Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

David Spigel • 29 Sep 2019
ESMO 2019
Breast Cancer Atezolizumab
IMpower110

Here, David Spigel, MD, Sarah Cannon Research Institute, Nashville, TN, provides an interim OS analysis of the Phase III IMpower110 study (NCT02409342) of atezolizumab vs platinum-based chemotherapy as a first-line treatment in PD-L1–selected non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from David Spigel

2:00
Lung cancer updates at ASCO 2021
David Spigel • 26 May 2021
4:46
5-year survival outcomes from the PACIFIC trial
David Spigel • 26 May 2021
3:37
CANOPY-A: canakinumab for early stage NSCLC
David Spigel • 28 May 2020
2:31
RESILIENT: liposomal irinotecan in relapsed SCLC
David Spigel • 28 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals